Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
← catalyst calendarNCT07157774 · readout ≤ 1,685 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
10,450estimated
Sites
785
Countries
Argentina, Australia, Austria +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-02 | actual | When the study began enrolling |
| Primary completion | Mar 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Elevated Lp(a)
- Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
- Drug: Muvalaplin — also filed as LY3473329
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint
measured Baseline up to End of Study (About 5.25 Years)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed